Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
288.6 SEK | +1.48% | +3.89% | +8.09% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 28.88 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.58 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.09% | 9.41B | B+ | ||
+0.99% | 91.72B | A- | ||
0.00% | 39.44B | A- | ||
-10.35% | 34.47B | B- | ||
+64.64% | 26.7B | A | ||
-16.15% | 15.13B | C | ||
-6.98% | 13.27B | B- | ||
-11.77% | 11.74B | D+ | ||
-49.19% | 10.54B | B | ||
+141.62% | 9.22B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB